IN THE SPOTLIGHT

Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review

Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review

Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations

Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC

Disruption of the intramolecular interaction between human lung cancer-related EGFR kinase domain and carboxy-terminal tail by intra-Tyr1016 phosphorylation or extra-peptidic competitors

Disruption of the intramolecular interaction between human lung cancer-related EGFR kinase domain and carboxy-terminal tail by intra-Tyr1016 phosphorylation or extra-peptidic competitors

EZR–ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review

EZR–ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

PFS 超 35 个月!奥希替尼联合化疗一线治疗 EGFR L858R 合并 TP53 共突变晚期肺癌病例分享_腾讯新闻

PFS 超 35 个月!奥希替尼联合化疗一线治疗 EGFR L858R 合并 TP53 共突变晚期肺癌病例分享_腾讯新闻

Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib

Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib

In silico evaluation of (benzo)chromeno[3,4-c]pyridine derivative as dual EGFR/HER2 inhibitors for non-small cell lung cancer

In silico evaluation of (benzo)chromeno[3,4-c]pyridine derivative as dual EGFR/HER2 inhibitors for non-small cell lung cancer